Publications

Bemarituzumab in Patients with Fgfr2B-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (Fight) : a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

AuthID
P-00X-D3K

Author(s)

Wainberg, ZA

Enzinger, PC

Kang, YK

Qin, SK

Yamaguchi, K

Kim, IH

Saeed, A

Oh, SC

Li, J

Turk, HM

[+1]·

Borg, C

Hitre, E

Udrea, AA

Cardellino, GG

Sanchez, RG

Collins, H

Mitra, S

Yang, YS

Catenacci, DVT

Lee, KW

View all authors

Document Type

Article

Year published

2022

Published

in LANCET ONCOLOGY, ISSN: 1470-2045

Volume: 23, Issue: 11, Pages: 1430-1440 (11)

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/s1470-2045(22)00603-9

Pubmed: 36244398

Scopus: 2-s2.0-85140889719

Wos: WOS:000886922400038

Source Identifiers

ISSN: 1470-2045

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

All authors

Name Order	Name	Name Order	Name	Name Order	Name
1	Wainberg, ZA;	2	Enzinger, PC;	3	Kang, YK;
4	Qin, SK;	5	Yamaguchi, K;	6	Kim, IH;
7	Saeed, A;	8	Oh, SC;	9	Li, J;
10	Turk, HM;	11	Teixeira, A;	12	Borg, C;
13	Hitre, E;	14	Udrea, AA;	15	Cardellino, GG;
16	Sanchez, RG;	17	Collins, H;	18	Mitra, S;
19	Yang, YS;	20	Catenacci, DVT;	21	Lee, KW;

Bemarituzumab in Patients with Fgfr2B-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (Fight) : a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

Useful Links

Get Help

Federated Authentication (Click on the image)

Bemarituzumab in Patients with Fgfr2B-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (Fight) : a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

Useful Links

Get Help